Major progress has been made in the past decade in understanding the pathogenesis and treatment of gout. These advances include identification of the genetic and environmental risk factors for gout, recognition that gout is an important risk factor for cardiovascular disease, elucidation of the pathways regulating the acute gout attack and the development of novel therapeutic agents to treat both the acute and chronic phases of the disease. This review summarises these advances and highlights the research agenda for the next decade.
Statistics from Altmetric.com
Funding AS receives support from the Fonds National Suisse de Recherche.
Competing interests AS has received consulting fees from Novartis. ND has no competing interests to declare.
Provenance and peer review Not commissioned; externally peer reviewed.